Needham & Company LLC began coverage on shares of Oculis (NASDAQ:OCS – Free Report) in a research report report published on Wednesday morning, Marketbeat.com reports. The firm issued a buy rating and a $36.00 target price on the stock.
Other research analysts also recently issued reports about the stock. HC Wainwright upped their price target on shares of Oculis from $32.00 to $33.00 and gave the stock a “buy” rating in a report on Friday, August 22nd. Chardan Capital boosted their price objective on Oculis from $28.00 to $33.00 and gave the stock a “buy” rating in a research report on Friday, May 9th. Four investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $35.75.
View Our Latest Stock Report on OCS
Oculis Stock Down 1.1%
Oculis (NASDAQ:OCS – Get Free Report) last announced its quarterly earnings results on Thursday, August 21st. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.06). The company had revenue of $0.25 million for the quarter, compared to the consensus estimate of $0.14 million. Oculis had a negative net margin of 13,958.12% and a negative return on equity of 90.31%. As a group, equities research analysts anticipate that Oculis will post -2.09 EPS for the current fiscal year.
Institutional Investors Weigh In On Oculis
Institutional investors have recently modified their holdings of the company. Bellevue Group AG acquired a new stake in shares of Oculis during the fourth quarter worth $170,000. Kestra Private Wealth Services LLC acquired a new position in Oculis in the first quarter valued at $234,000. Geode Capital Management LLC boosted its position in Oculis by 12.0% during the fourth quarter. Geode Capital Management LLC now owns 16,744 shares of the company’s stock valued at $284,000 after acquiring an additional 1,800 shares during the last quarter. Bosun Asset Management LLC acquired a new stake in Oculis during the 2nd quarter worth about $378,000. Finally, Citadel Advisors LLC acquired a new stake in Oculis during the 4th quarter worth about $389,000. 22.30% of the stock is owned by institutional investors.
Oculis Company Profile
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Further Reading
- Five stocks we like better than Oculis
- What does consumer price index measure?
- Amazon’s Chart Just Flashed a Pennant Pattern—Here’s What to Do
- Investing In Automotive Stocks
- 3 Undervalued Stocks Analysts Are Loving Right Now—Should You?
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Williams-Sonoma Q2 Results Prove Its Buy-and-Hold Quality
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.